Freedom Investment Management Inc. Buys Shares of 12,870 Hims & Hers Health, Inc. $HIMS

Key Points

• Freedom Investment Management Inc. has invested approximately $380,000 in Hims & Hers Health, acquiring 12,870 shares in the first quarter of 2023.
• A significant percentage of Hims & Hers Health's stock is controlled by institutional investors, with over 63.52% of shares held by hedge funds and institutions.
• Hims & Hers Health reported a year-over-year revenue increase of 72.6% for the last quarter, although it missed earnings expectations with $0.17 earnings per share versus a consensus estimate of $0.18.

Freedom Investment Management Inc. purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,870 shares of the company's stock, valued at approximately $380,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Smartleaf Asset Management LLC increased its stake in Hims & Hers Health by 15.7% during the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company's stock worth $49,000 after purchasing an additional 227 shares during the period. Allworth Financial LP increased its stake in Hims & Hers Health by 20.0% during the first quarter. Allworth Financial LP now owns 2,006 shares of the company's stock worth $56,000 after purchasing an additional 334 shares during the period. Signaturefd LLC increased its stake in Hims & Hers Health by 17.7% during the first quarter. Signaturefd LLC now owns 2,586 shares of the company's stock worth $76,000 after purchasing an additional 388 shares during the period. Larson Financial Group LLC increased its stake in Hims & Hers Health by 47.7% during the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock worth $42,000 after purchasing an additional 458 shares during the period. Finally, Cim LLC increased its stake in Hims & Hers Health by 1.0% during the fourth quarter. Cim LLC now owns 71,869 shares of the company's stock worth $1,738,000 after purchasing an additional 694 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CFO Oluyemi Okupe sold 23,107 shares of Hims & Hers Health stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $47.25, for a total value of $1,091,805.75. Following the transaction, the chief financial officer directly owned 63,222 shares in the company, valued at $2,987,239.50. This trade represents a 26.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Andrew Dudum sold 660,000 shares of Hims & Hers Health stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the completion of the transaction, the chief executive officer owned 2,214,769 shares in the company, valued at approximately $112,023,016.02. This trade represents a 22.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,395,428 shares of company stock valued at $71,753,898. Corporate insiders own 13.71% of the company's stock.

Hims & Hers Health Stock Performance

Shares of HIMS stock traded down $1.76 during trading hours on Friday, hitting $42.36. The stock had a trading volume of 16,080,388 shares, compared to its average volume of 29,952,310. The firm has a market capitalization of $9.57 billion, a PE ratio of 52.95, a PEG ratio of 2.98 and a beta of 2.08. Hims & Hers Health, Inc. has a twelve month low of $13.47 and a twelve month high of $72.98. The stock's 50 day moving average is $49.98 and its 200 day moving average is $45.82. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. Hims & Hers Health's revenue was up 72.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on HIMS shares. Truist Financial cut their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research note on Monday, August 18th. Wall Street Zen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Finally, Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Hims & Hers Health has a consensus rating of "Reduce" and an average target price of $38.92.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.